Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference23 articles.
1. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J Clin Oncol,2001
2. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011
3. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N Engl J Med,2011
4. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC);Pujade-Lauraine;J Clin Oncol,2012
5. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J Clin Oncol,2012
Cited by 52 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis;International Journal of Gynecologic Cancer;2024-04-23
2. Evaluation of Circulating Cell-Free DNA Levels in Predicting Operability During Interval Cytoreduction for Advanced Epithelial Ovarian Cancers;Indian Journal of Gynecologic Oncology;2024-03-04
3. Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer;Biology;2024-01-31
4. Advances and Challenges in the Use of Liquid Biopsy in Gynaecological Oncology;2024
5. Liquid biopsy: creating opportunities in brain space;British Journal of Cancer;2023-09-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3